MedTrace Logo

Liq-NOL Efficacy in Pediatric Patients With Down Syndrome

NCT00891917 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-09-09

No results posted yet for this study

Summary

The purpose of this study is to measure the effects of LiQ-NOL supplementation on language production using the Clinical Evaluation of Language Fundamentals test, language sampling using the mean length of utterance test, and speech articulation using the Goldman-Fristoe Test of Articulation.

Conditions

  • Down Syndrome

Interventions

DIETARY_SUPPLEMENT

Ubiquinol-10 Syrup

10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months

DIETARY_SUPPLEMENT

syrup (placebo)

syrup looks exactly like the Ubiquinol-10 Syrup but has no active ingredients or supplementation

Sponsors & Collaborators

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Michael V Miles, Pharm.D. · Childrens Hospital Medical Center, Cincinnati

  • Francis Hickey, M.D. · Childrens Hospital Medical Center, Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2012-11-30
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00891917 on ClinicalTrials.gov